1st Quarter - Amendment

TAKEDA PHARMACEUTICALS AMERICA, INC. for TAKEDA PHARMACEUTICALS AMERICA INC

Firm
Client
Income
—
Expenses
$445,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 20, 2011 $455,000 Replaced
1st Quarter - Amendment (this page) Jul 20, 2011 $445,000 Yes

What was lobbied

9 issue areas, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

S. 3036 National Alzheimers Project Act

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: Centers For Medicare and Medicaid Services (CMS); Treasury, Dept of; SENATE; Food & Drug Administration (FDA); Agency for Healthcare Research & Quality (AHRQ); Medicare Payment Advisory Commission (MedPAC); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD)

Bills named: S. 3036 (112th)

Budget/Appropriations BUD

5th Continuing Resolution HJRes44; 6th Continuing Resolution HJRes48; Department of Defense and Further Additional Continuing Appropriations Act, 2011 H1363; Department of Defense and Full-Year Continuing Appropriations Act, 2011 H1473;

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: Medicare Payment Advisory Commission (MedPAC); Defense, Dept of (DOD); Treasury, Dept of; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); SENATE; Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.J.Res. 44 (112th), H.J.Res. 48 (112th)

Law Enforcement/Crime/Criminal Justice LAW

HR 816 Provider Shield Act of 2011 Medical malpractice reforms

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Medicare Payment Advisory Commission (MedPAC); Food & Drug Administration (FDA); Treasury, Dept of; Defense, Dept of (DOD)

Bills named: H.R. 816 (112th)

Taxation/Internal Revenue Code TAX

Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt and deficit commission recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act section 9006, referred to as 1099 provision; Innovate America Act; Ryan Roadmap;

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); Treasury, Dept of; Agency for Healthcare Research & Quality (AHRQ); Defense, Dept of (DOD); SENATE; Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Importation issues, Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act;

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: Health Resources & Services Administration (HRSA); Treasury, Dept of; Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Agency for Healthcare Research & Quality (AHRQ); SENATE; Defense, Dept of (DOD)

Bills named: S. 319 (112th)

Manufacturing MAN

Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act;

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: Defense, Dept of (DOD); Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); Agency for Healthcare Research & Quality (AHRQ); Treasury, Dept of; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); SENATE

Bills named: S. 319 (112th)

Copyright/Patent/Trademark CPT

S. 23 Patent Reform Act of 2011; S. 27 Preserve Access to Affordable Generics

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: Health Resources & Services Administration (HRSA); Treasury, Dept of; Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; Agency for Healthcare Research & Quality (AHRQ); Medicare Payment Advisory Commission (MedPAC)

Bills named: S. 27 (112th), S. 23 (112th)

Health Issues HCR

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute

LobbyistCovered position, as disclosed
LAURA ELIZABETH CLINE —
DEBORAH LYNN WALTER —
ANDREA WILKINSON —

Contacted: Treasury, Dept of; SENATE; Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD)

Bills named: S. 371 (112th), H.R. 2 (112th), H.R. 741 (112th)

Medicare/Medicaid MMM

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap ;

LobbyistCovered position, as disclosed
LAURA ELIZABETH CLINE —
DEBORAH LYNN WALTER —
ANDREA WILKINSON —

Contacted: Agency for Healthcare Research & Quality (AHRQ); Treasury, Dept of; Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD)

Bills named: S. 44 (112th), H.R. 457 (112th), S. 31 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.